

# Understanding Lived Experiences with KCNQ2-Developmental and Epileptic Encephalopathy (KCNQ2-DEE)

Michele H Potashman,<sup>1</sup> Katja Rudell,<sup>2</sup> Linda Abetz-Webb,<sup>3</sup> Naomi Suminski,<sup>2</sup> Audra Gold,<sup>4</sup> Rinchen Doma,<sup>2</sup> Kavita Jarodia,<sup>2</sup> Chris Buckley,<sup>2</sup> Matthew Ridley,<sup>2</sup> Jason Lerner,<sup>1</sup> Jim Mather,<sup>1</sup> Vlad Coric,<sup>1</sup> John Millichap,<sup>5,6</sup> Anne T Berg,<sup>5,7</sup> Gil L'Italien<sup>1</sup>

<sup>1</sup>Biohaven Pharmaceuticals Inc., New Haven, CT, USA; <sup>2</sup>COA Science, Parexel International, London, UK; <sup>3</sup>Patient-Centred Outcomes Assessments, Macclesfield, UK; <sup>4</sup>RTI Health Solutions, Research Triangle Park, NC, USA; <sup>5</sup>Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; <sup>6</sup>Precision Epilepsy PLLC, Chicago, IL, USA; <sup>7</sup>DEE-P Connections, Washington, DC, USA

**CONFLICTS OF INTEREST:** This study was funded by Biohaven Pharmaceuticals Inc. MHP, JL, J Mather and GL are employed by and hold stock/stock options in Biohaven Pharmaceuticals Inc. ATB has received fees from Biogen, Biohaven Pharmaceuticals Inc., Biomarin and Encoded Therapeutics. J Millichap has received fees from Biohaven Pharmaceuticals Inc., Biomarin, Eisai, Greenwich, Neurocrine, Praxis, UpToDate and Xenon, and serves on the board of directors for Child Neurology Foundation. KR, LA-W, NS, AG, RD, KJ, CB and MR were commissioned by Biohaven Pharmaceuticals Inc. to conduct the study.

## INTRODUCTION

- KCNQ2 developmental and epileptic encephalopathy (DEE) is a rare neurodevelopmental disorder impacting approximately six in every 100,000 live births<sup>1,2</sup>
- KCNQ2-DEE is caused by variants in the *KCNQ2* gene, which encodes the K<sub>v</sub>7.2 subunit of the voltage-gated potassium channel<sup>2</sup>
- Children with KCNQ2-DEE typically present with seizures within the first few days of life and neurodevelopmental impairments<sup>1,2</sup>
- Prior outcomes research in the KCNQ2-DEE population has focused on characterising functional impairments and clinical outcomes in individuals with KCNQ2-DEE<sup>2-4</sup> with limited qualitative interview data outlining the patient and caregiver disease-related experiences and impact of the disorder

## OBJECTIVE

- Develop KCNQ2-DEE conceptual models outlining the burden of seizures, extent of neurodevelopmental delays and impact of the disease on quality of life from the perspectives of parents of children with KCNQ2-DEE

## METHODS

- Semi-structured interviews were conducted via video call with United States-based parental caregivers of children (aged 1–18 years) with mild, severe and profound KCNQ2-DEE phenotypes between September and November 2023
- Eligible parents were recruited via a patient advocacy group (KCNQ2 Cure Alliance)
- Interviews consisted of three parts: collection of background information; concept elicitation to understand the signs, symptoms and impacts of KCNQ2-DEE; and descriptions of patient severity and associated developmental impacts. The most burdensome disease aspects were discussed (rated on a 0–10 scale)
- Interviews were audio recorded, transcribed, coded and analysed by ATLAS.Ti v23 software, following established methods
- Interviews were assessed for concept saturation and four conceptual models were derived – one for each KCNQ2-DEE phenotype severity and one overall model

## RESULTS

### Demographics

- Interviews were conducted with 53 parents of children with KCNQ2-DEE (N=54 children)
- Demographics and clinical characteristics are presented in **Table 1**
  - Most (77%) parents interviewed were mothers
  - The mean age of children with KCNQ2-DEE was 7.3 years and most were classed as having a severe KCNQ2-DEE phenotype (mild, 31.5%; severe, 50.0%; profound, 18.5%)

**Table 1. Parent and child demographics and clinical characteristics**

Parent demographics	N=53 <sup>a</sup>
Age in years, mean (range)	42.3 (28–58)
Relationship with child, n (%)	
Mother	41 (77.4)
Father	13 (24.5)
Hours spent with child in last week, mean (range)	112 (20–168)
Child demographics and clinical characteristics	N=54
Age in years, mean (range)	7.3 (1–18)
Child sex, n (%)	
Male	25 (46.3)
Female	29 (53.7)
Diagnosis, n (%)	
Genetic test in medical record	3 (5.6)
Genetic test/panel	51 (94.4)
Severity of KCNQ2-DEE phenotype, <sup>b</sup> n (%)	
Mild	17 (31.5)
Severe	27 (50.0)
Profound	10 (18.5)

DEE, developmental and epileptic encephalopathy.  
<sup>a</sup>One parent had twins with KCNQ2-DEE; <sup>b</sup>Severity definition based on degree of impairments across gross motor function, communication (ages 2–18 years only) and chewing ability.


### Concept elicitation: signs and symptoms of KCNQ2-DEE

- Parents were asked to describe the daily limitations or difficulties related to their child with KCNQ2-DEE
- The most frequently reported signs, symptoms and functional limitations are shown in **Figure 1**
  - Overall, the most common concepts parents reported were difficulties with communication (88.9%), and gross (81.5%) and fine (63.0%) motor problems (**Figure 1**)
  - Generally, more parents of children with severe KCNQ2-DEE reported issues than parents of children with mild KCNQ2-DEE (**Figure 1**)

### Most bothersome and impactful issues associated with KCNQ2-DEE

- Parents were asked to indicate the issues they considered to be particularly impactful or bothersome
  - Difficulty with communication (74.1%), behavioural disorders (37.0%) and gross motor problems (24.1%) were the most impactful and bothersome issues for parents (**Table 2**)
  - When asked about the single most bothersome concept, communication was most frequently mentioned (27.8%) (**Table 2**)

**Figure 1. Frequently reported concepts from >10% of parents of children with KCNQ2-DEE**




**Table 2. Concepts reported as most bothersome and impactful for parents**

Concept	Concepts reported as bothersome or impactful to parent, <sup>a,b</sup> n (%)	Most bothersome to parent, n (%)
Communication	40 (74.1)	15 (27.8)
Gross motor skills	13 (24.1)	5 (9.3)
Fine motor skills	2 (3.7)	0 (0)
Personal care and hygiene	7 (13.0)	1 (1.9)
Bulbar function	5 (9.3)	3 (5.6)
Behavioural disorder	20 (37.0)	8 (14.8)
Autonomic nervous system	4 (7.4)	5 (9.3)
Seizures	2 (3.7)	1 (1.9)
Cognition	7 (13.0)	3 (5.6)
Parental burden	6 (11.1)	3 (5.6)
Sleep	3 (5.6)	1 (1.9)

<sup>a</sup>Counts were not mutually exclusive; some parents reported multiple concepts; <sup>b</sup>One parent had twins with KCNQ2-DEE.

- Following this, parents (N=53) were asked to rate how impacted they were by each concept using a 10-point rating scale (0 = 'not impacted' to 10 = 'extremely impacted')
  - The most burdensome symptoms were difficulty with communication (mean score [SD] = 8.6 [1.7]; 87.0% parents), cognitive delays (8.1 [2.0]; 37.0% parents), and personal care and hygiene issues (7.4 [2.2]; 29.6% parents) (**Figure 2**)
  - Seizures were the least burdensome symptom (mean score [SD] = 5.3 [3.6]; 87.0% parents) (**Figure 2**); parents reported that seizure occurrence was now infrequent versus in infancy
- Together, these data informed the development of a KCNQ2-DEE conceptual model (**Supplementary Figure**)

**Figure 2. Parent rating for concepts considered most impactful**



## CONCLUSIONS

- KCNQ2-DEE is a multi-faceted disease with wide ranging developmental and neurological impairments that impact both children and their parents
- Of concepts reported by parents of children with varying KCNQ2-DEE phenotypes, communication difficulties, cognitive delays, and issues with personal care and hygiene were the most bothersome
- Parents indicated that seizures were the least bothersome symptom post-infancy
- Together, these findings identify outcome domains important to parents and children with KCNQ2-DEE, and may inform the development of measurement tools and endpoint selection in future therapeutic trials



# Understanding Lived Experiences with KCNQ2-Developmental and Epileptic Encephalopathy (KCNQ2-DEE) Supplementary Material

Michele H Potashman,<sup>1</sup> Katja Rudell,<sup>2</sup> Linda Abetz-Webb,<sup>3</sup> Naomi Suminski,<sup>2</sup> Audra Gold,<sup>4</sup> Rinchen Doma,<sup>2</sup> Kavita Jarodia,<sup>2</sup> Chris Buckley,<sup>2</sup> Matthew Ridley,<sup>2</sup> Jason Lerner,<sup>1</sup> Jim Mather,<sup>1</sup> Vlad Coric,<sup>1</sup> John Millichap,<sup>5,6</sup> Anne T Berg,<sup>5,7</sup> Gil L'Italien<sup>1</sup>

<sup>1</sup>Biohaven Pharmaceuticals Inc., New Haven, CT, USA; <sup>2</sup>COA Science, Parexel International, London, UK; <sup>3</sup>Patient-Centred Outcomes Assessments, Macclesfield, UK; <sup>4</sup>RTI Health Solutions, Research Triangle Park, NC, USA; <sup>5</sup>Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; <sup>6</sup>Precision Epilepsy PLLC, Chicago, IL, USA; <sup>7</sup>DEE-P Connections, Washington, DC, USA

